Cipher Pharmaceuticals Inc
TSX:CPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.45
18.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc
Net Income (Common)
Cipher Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Net Income (Common)
$15.9m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Income (Common)
-$178m
|
CAGR 3-Years
47%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Net Income (Common)
-CA$172.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Income (Common)
-$47.4m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income (Common)
-$97.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-144%
|
CAGR 10-Years
-99%
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Net Income (Common)
-$588.1m
|
CAGR 3-Years
-124%
|
CAGR 5-Years
-347%
|
CAGR 10-Years
N/A
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
15.9m
USD
Based on the financial report for Sep 30, 2024, Cipher Pharmaceuticals Inc's Net Income (Common) amounts to 15.9m USD.
What is Cipher Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-7%
Over the last year, the Net Income (Common) growth was -51%. The average annual Net Income (Common) growth rates for Cipher Pharmaceuticals Inc have been 48% over the past three years , and -7% over the past ten years .
You don't have any saved screeners yet
